{"paper_id":"b316d862-f7c9-4276-8fd1-2b4cfb0133ac","body_text":"Abstract\nPurpose\nMenstrual pain is associated with increased production of inflammatory molecules, such as prostaglandins. Inflammation is involved in pathogenesis of several cancers, including ovarian cancer. In this study, we examined the association between menstrual pain and risk of ovarian cancer.\nMethods\nWe conducted a case–control study with 2,028 cases of epithelial ovarian cancer and 2,091 age- and study center-matched controls. Women were asked to report the severity of menstrual pain during their twenties and thirties, when not using oral contraceptives or breastfeeding. We used an unconditional logistic regression to evaluate the association between menstrual pain and epithelial ovarian cancer risk overall, and polytomous logistic regression to evaluate whether the association differed across tumor subtypes.\nResults\nRisk of ovarian cancer was increased in women with moderate (OR 1.22, 95 % CI 1.05–1.42) and severe pain (OR 1.34, 95 % CI 1.09–1.65) compared to women with no or mild pain during menstrual period. The association differed by histologic subtypes, with significant associations for severe pain with endometrioid (OR 1.64, 95 % CI 1.15–2.34) and clear cell tumors (OR 1.91, 95 % CI 1.11–3.28).\nConclusions\nOur data suggest that moderate and severe pain during menstrual period are associated with increased risk of epithelial ovarian cancer. Due to high prevalence of menstrual pain in women of reproductive age, this observation warrants further studies.\nReferences\nAmerican Cancer Society. Cancer facts & figures 2013. Atlanta (GA). 2013\nCramer DW, Welch WR (1983) Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J Natl Cancer Inst 71:717–721\nFathalla MF (1971) Incessant ovulation—a factor in ovarian neoplasia? Lancet 2:163\nRisch HA (1998) Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst 90:1774–1786\nTerry KL, Karageorgi S, Shvetsov YB, Merritt MA, Lurie G, Thompson PJ et al (2013) Genital powder use and risk of ovarian cancer: a pooled analysis of 8,525 cases and 9,859 controls. Cancer Prev Res (Phila) 6:811–821\nHankinson SE, Hunter DJ, Colditz GA, Willett WC, Stampfer MJ, Rosner B et al (1993) Tubal ligation, hysterectomy, and risk of ovarian cancer. A prospective study. Jama 270:2813–2818\nIrwin KL, Weiss NS, Lee NC, Peterson HB (1991) Tubal sterilization, hysterectomy, and the subsequent occurrence of epithelial ovarian cancer. Am J Epidemiol 134:362–369\nSieh W, Salvador S, McGuire V, Weber RP, Terry KL, Rossing MA et al (2013) Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case–control studies. Int J Epidemiol 42:579–589\nPearce CL, Templeman C, Rossing MA, Lee A, Near AM, Webb PM et al (2012) Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case–control studies. Lancet Oncol 13:385–394\nNess RB, Cottreau C (1999) Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst 91:1459–1467\nLentz G, Lobo R, Gershenson D et al (2012) Comprehensive gynecology Philadelphia. Elsevier, Mosby, PA\nDawood MY (1990) Dysmenorrhea. Clin Obstet Gynecol 33:168–178\nBenedetto C (1989) Eicosanoids in primary dysmenorrhea, endometriosis and menstrual migraine. Gynecol Endocrinol 3:71–94\nChan WY, Hill JC (1978) Determination of menstrual prostaglandin levels in non-dysmenorrheic and dysmenorrheic subjects. Prostaglandins 15:365–375\nJabbour HN, Sales KJ, Smith OP, Battersby S, Boddy SC (2006) Prostaglandin receptors are mediators of vascular function in endometrial pathologies. Mol Cell Endocrinol 252:191–200\nNigam S, Benedetto C, Zonca M, Leo-Rossberg I, Lubbert H, Hammerstein J (1991) Increased concentrations of eicosanoids and platelet-activating factor in menstrual blood from women with primary dysmenorrhea. Eicosanoids 4:137–141\nPowell AM, Chan WY, Alvin P, Litt IF (1985) Menstrual-PGF2 alpha, PGE2 and TXA2 in normal and dysmenorrheic women and their temporal relationship to dysmenorrhea. Prostaglandins 29:273–290\nBieglmayer C, Hofer G, Kainz C, Reinthaller A, Kopp B, Janisch H (1995) Concentrations of various arachidonic acid metabolites in menstrual fluid are associated with menstrual pain and are influenced by hormonal contraceptives. Gynecol Endocrinol 9:307–312\nRees MC, DiMarzo V, Tippins JR, Morris HR, Turnbull AC (1987) Leukotriene release by endometrium and myometrium throughout the menstrual cycle in dysmenorrhoea and menorrhagia. J Endocrinol 113:291–295\nIkai K (1999) Psoriasis and the arachidonic acid cascade. J Dermatol Sci 21:135–146\nSperling RI (1995) Eicosanoids in rheumatoid arthritis. Rheum Dis Clin North Am 21:741–758\nSharon P, Stenson WF (1984) Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease. Gastroenterology 86:453–460\nRigas B, Goldman IS, Levine L (1993) Altered eicosanoid levels in human colon cancer. J Lab Clin Med 122:518–523\nEberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN (1994) Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107:1183–1188\nTitus-Ernstoff L, Perez K, Cramer DW, Harlow BL, Baron JA, Greenberg ER (2001) Menstrual and reproductive factors in relation to ovarian cancer risk. Br J Cancer 84:714–721\nHarris HR, Cramer DW, Vitonis AF, DePari M, Terry KL (2012) Folate, vitamin B(6), vitamin B(12), methionine and alcohol intake in relation to ovarian cancer risk. Int J Cancer 131:E518–E529\nTerry KL, De Vivo I, Titus-Ernstoff L, Sluss PM, Cramer DW (2005) Genetic variation in the progesterone receptor gene and ovarian cancer risk. Am J Epidemiol 161:442–451\nMarshall RJ, Chisholm EM (1985) Hypothesis testing in the polychotomous logistic model with an application to detecting gastrointestinal cancer. Stat Med 4:337–344\nKotsopoulos J, Terry KL, Poole EM, Rosner B, Murphy MA, Hecht JL et al (2013) Ovarian cancer risk factors by tumor dominance, a surrogate for cell of origin. Int J Cancer 133:730–739\nPoole EM, Merritt MA, Jordan SJ, Yang HP, Hankinson SE, Park Y et al (2013) Hormonal and reproductive risk factors for epithelial ovarian cancer by tumor aggressiveness. Cancer Epidemiol Biomarkers Prev 22:429–437\nChen Y, Wu PC, Lang JH, Ge WJ, Hartge P, Brinton LA (1992) Risk factors for epithelial ovarian cancer in Beijing, China. Int J Epidemiol 21:23–29\nTung KH, Goodman MT, Wu AH, McDuffie K, Wilkens LR, Kolonel LN et al (2003) Reproductive factors and epithelial ovarian cancer risk by histologic type: a multiethnic case–control study. Am J Epidemiol 158:629–638\nMerritt MA, Green AC, Nagle CM, Webb PM (2008) Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer. Int J Cancer 122:170–176\nMcGowan L, Parent L, Lednar W, Norris HJ (1979) The woman at risk for developing ovarian cancer. Gynecol Oncol 7:325–344\nPurdie D, Green A, Bain C, Siskind V, Ward B, Hacker N et al (1995) Reproductive and other factors and risk of epithelial ovarian cancer: an Australian case–control study. Survey of Women’s Health Study Group. Int J Cancer 62:678–684\nWynder EL, Dodo H, Barber HR (1969) Epidemiology of cancer of the ovary. Cancer 23:352–370\nVercellini P, Vigano P, Somigliana E, Fedele L (2013) Endometriosis: pathogenesis and treatment. Nat Rev Endocrinol 10(5):261\nRossing MA, Cushing-Haugen KL, Wicklund KG, Doherty JA, Weiss NS (2008) Risk of epithelial ovarian cancer in relation to benign ovarian conditions and ovarian surgery. Cancer Causes Control 19:1357–1364\nMissmer SA, Hankinson SE, Spiegelman D, Barbieri RL, Marshall LM, Hunter DJ (2004) Incidence of laparoscopically confirmed endometriosis by demographic, anthropometric, and lifestyle factors. Am J Epidemiol 160:784–796\nLundstrom V, Green K (1978) Endogenous levels of prostaglandin F2alpha and its main metabolites in plasma and endometrium of normal and dysmenorrheic women. Am J Obstet Gynecol 130:640–646\nRees MC, Anderson AB, Demers LM, Turnbull AC (1984) Prostaglandins in menstrual fluid in menorrhagia and dysmenorrhoea. Br J Obstet Gynaecol 91:673–680\nChan WY, Dawood MY, Fuchs F (1981) Prostaglandins in primary dysmenorrhea. Comparison of prophylactic and nonprophylactic treatment with ibuprofen and use of oral contraceptives. Am J Med 70:535–541\nHensler S, Mueller MM (2013) Inflammation and skin cancer: old pals telling new stories. Cancer J 19:517–524\nOhd JF, Nielsen CK, Campbell J, Landberg G, Lofberg H, Sjolander A (2003) Expression of the leukotriene D4 receptor CysLT1, COX-2, and other cell survival factors in colorectal adenocarcinomas. Gastroenterology 124:57–70\nZhou Y, Guo D, Li H, Jie S (2011) Circulating LTD4 in patients with hepatocellular carcinoma. Tumour Biol 32:139–144\nBlumenkrantz MJ, Gallagher N, Bashore RA, Tenckhoff H (1981) Retrograde menstruation in women undergoing chronic peritoneal dialysis. Obstet Gynecol 57:667–670\nHalme J, Hammond MG, Hulka JF, Raj SG, Talbert LM (1984) Retrograde menstruation in healthy women and in patients with endometriosis. Obstet Gynecol 64:151–154\nLiu DT, Hitchcock A (1986) Endometriosis: its association with retrograde menstruation, dysmenorrhoea and tubal pathology. Br J Obstet Gynaecol 93:859–862\nAuersperg N, Maines-Bandiera SL, Dyck HG (1997) Ovarian carcinogenesis and the biology of ovarian surface epithelium. J Cell Physiol 173:261–265\nMurdoch WJ (1996) Ovarian surface epithelium, ovulation and carcinogenesis. Biol Rev Camb Philos Soc 71:529–543\nJu H, Jones M, Mishra G (2013) The Prevalence and Risk Factors of Dysmenorrhea. Epidemiol Rev\nAcknowledgments\nThis work was supported by the National Cancer Institute at the National Institutes of Health (R01CA54419, P50CA105009, and 5T32CA009001-38), and the Department of Defense (W81XWH-10-1-0280).\nConflict of interest\nThe authors declare that they have no conflict of interest.\nAuthor information\nAuthors and Affiliations\nCorresponding author\nRights and permissions\nAbout this article\nCite this article\nBabic, A., Cramer, D.W., Titus, L.J. et al. Menstrual pain and epithelial ovarian cancer risk. Cancer Causes Control 25, 1725–1731 (2014). https://doi.org/10.1007/s10552-014-0463-6\nReceived:\nAccepted:\nPublished:\nIssue date:\nDOI: https://doi.org/10.1007/s10552-014-0463-6","source_license":"CC0","license_restricted":false}